INCANNEX HEALTHCARE INC (IXHL) Stock Price & Overview

NASDAQ:IXHL • US45333F2083

Current stock price

4.09 USD
+0.32 (+8.49%)
At close:
4.07 USD
-0.02 (-0.49%)
Pre-Market:

The current stock price of IXHL is 4.09 USD. Today IXHL is up by 8.49%. In the past month the price increased by 47.12%. In the past year, price decreased by -76.53%.

IXHL Key Statistics

52-Week Range2.4 - 49.8
Current IXHL stock price positioned within its 52-week range.
1-Month Range2.49 - 4.19
Current IXHL stock price positioned within its 1-month range.
Market Cap
57.137M
P/E
N/A
Fwd P/E
3.16
EPS (TTM)
-255.48
Dividend Yield
N/A

IXHL Stock Performance

Today
+8.49%
1 Week
+12.67%
1 Month
+47.12%
3 Months
-60.38%
Longer-term
6 Months -60.98%
1 Year -76.53%
2 Years -95.28%
3 Years -98.42%
5 Years N/A
10 Years N/A

IXHL Stock Chart

INCANNEX HEALTHCARE INC / IXHL Daily stock chart

IXHL Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to IXHL. When comparing the yearly performance of all stocks, IXHL is a bad performer in the overall market: 98.02% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

IXHL Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to IXHL. No worries on liquidiy or solvency for IXHL as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

IXHL Earnings

Next Earnings DateMay 13, 2026
Last Earnings DateFeb 13, 2026
PeriodQ2 / 2026
EPS Reported-$0.60
Revenue Reported
EPS Surprise 36.50%
Revenue Surprise %

IXHL Forecast & Estimates

For the next year, analysts expect an EPS growth of 99.78% and a revenue growth -100% for IXHL


Analysts
AnalystsN/A
Price TargetN/A
EPS Next Y99.78%
Revenue Next Year-100%

IXHL Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

IXHL Financial Highlights

Over the last trailing twelve months IXHL reported a non-GAAP Earnings per Share(EPS) of -255.48. The EPS increased by 55.63% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-48.50M
Industry RankSector Rank
PM (TTM) N/A
ROA -64.66%
ROE -66.07%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%99.79%
Sales Q2Q%-100%
EPS 1Y (TTM)55.63%
Revenue 1Y (TTM)-100%

IXHL Ownership

Ownership
Inst Owners2.89%
Shares13.97M
Float12.50M
Ins Owners10.56%
Short Float %6.52%
Short Ratio0.21

About IXHL

Company Profile

IXHL logo image Incannex Healthcare Inc is a AU-based company operating in Pharmaceuticals industry. Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.

Company Info

IPO: 2022-03-18

INCANNEX HEALTHCARE INC

8 Century Circuit, Ste. 105, Norwest

New York City NEW SOUTH WALES AU

Employees: 12

IXHL Company Website

IXHL Investor Relations

Phone: 18004831140

INCANNEX HEALTHCARE INC / IXHL FAQ

What does INCANNEX HEALTHCARE INC do?

Incannex Healthcare Inc is a AU-based company operating in Pharmaceuticals industry. Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.


What is the stock price of INCANNEX HEALTHCARE INC today?

The current stock price of IXHL is 4.09 USD. The price increased by 8.49% in the last trading session.


What is the dividend status of INCANNEX HEALTHCARE INC?

IXHL does not pay a dividend.


How is the ChartMill rating for INCANNEX HEALTHCARE INC?

IXHL has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


What sector and industry does INCANNEX HEALTHCARE INC belong to?

INCANNEX HEALTHCARE INC (IXHL) operates in the Health Care sector and the Pharmaceuticals industry.


What is the expected growth for IXHL stock?

The Revenue of INCANNEX HEALTHCARE INC (IXHL) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


What is INCANNEX HEALTHCARE INC worth?

INCANNEX HEALTHCARE INC (IXHL) has a market capitalization of 57.14M USD. This makes IXHL a Micro Cap stock.